D.E. Shaw & Co
IOVA icon

D.E. Shaw & Co’s Iovance Biotherapeutics IOVA Stock Holding History

D.E. Shaw & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-84,200
Closed -$1.25M – 4648
2024
Q1 		$1.25M Buy
+84,200
New +$980K ﹤0.01% 2948
2022
Q1 		– Sell
-30,500
Closed -$582K – 5730
2021
Q4 		$582K Hold
30,500
– – ﹤0.01% 4317
2021
Q3 		$752K Hold
30,500
– – ﹤0.01% 3812
2021
Q2 		$794K Buy
+30,500
New +$793K ﹤0.01% 3731

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

D.E. Shaw & Co's IOVA Position: Q1 2026 in Review

D.E. Shaw & Co increased its Iovance Biotherapeutics (IOVA) stake by 109% in Q1 2026, buying an estimated $13.4M and bringing the position to 8,016,353 shares worth $28.1M. The position accounts for 0.02% of the portfolio, ranked #943.

D.E. Shaw & Co first reported a position in IOVA in Q2 2015 and has held it in 31 quarters since. The position peaked at $34.9M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • D.E. Shaw & Co held 8,016,353 shares of Iovance Biotherapeutics worth $28.1M as of Q1 2026.
  • D.E. Shaw & Co bought 4,186,558 Iovance Biotherapeutics shares in Q1 2026, an estimated $13.4M.
  • Iovance Biotherapeutics made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #943 holding.
  • D.E. Shaw & Co first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 31 quarters since.
  • D.E. Shaw & Co's Iovance Biotherapeutics position peaked at $34.9M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.